A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Nitisinone (Primary)
- Indications Tyrosinaemia type I
- Focus Adverse reactions
- Acronyms OPAL
- Sponsors Swedish Orphan Biovitrum
- 29 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
- 29 May 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
- 22 Dec 2014 New trial record